Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit

Abstract excerpt

Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy. Surgical removal and chemotherapy are commonly used to treat uLMS, but recurrence rates are high. Over the last few decades, clarification of the genomic landscape of uLMS has revealed a number of recurring mutations, including TP53, RB1, ATRX, PTEN, and MED12. Such genomic aberrations are difficult to target therapeutically or are...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Ovarian cancer diagnosis and treatment
• Share to Sarcoma Diagnosis and Treatment
• Share to Uterine Myomas and Treatments